These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 10630409

  • 1. Overexpression of a dominant-negative type II TGFbeta receptor tagged with green fluorescent protein inhibits the effects of TGFbeta on cell growth and gene expression of mouse adrenal tumor cell line Y-1 and enhances cell tumorigenicity.
    Le Roy C, Maisnier-Patin K, Leduque P, Li JY, Saez JM, Langlois D.
    Mol Cell Endocrinol; 1999 Dec 20; 158(1-2):87-98. PubMed ID: 10630409
    [Abstract] [Full Text] [Related]

  • 2. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
    Yamamoto N, Imai J, Watanabe M, Hiroi N, Sugano S, Yoshino G.
    Horm Metab Res; 2006 Mar 20; 38(3):159-66. PubMed ID: 16673206
    [Abstract] [Full Text] [Related]

  • 3. Downregulation of TGFbeta isoforms and their receptors contributes to keratinocyte hyperproliferation in psoriasis vulgaris.
    Doi H, Shibata MA, Kiyokane K, Otsuki Y.
    J Dermatol Sci; 2003 Oct 20; 33(1):7-16. PubMed ID: 14527734
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of transforming growth factor beta-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells.
    Turco A, Coppa A, Aloe S, Baccheschi G, Morrone S, Zupi G, Colletta G.
    Int J Cancer; 1999 Jan 05; 80(1):85-91. PubMed ID: 9935236
    [Abstract] [Full Text] [Related]

  • 5. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells.
    Wang J, Han W, Zborowska E, Liang J, Wang X, Willson JK, Sun L, Brattain MG.
    J Biol Chem; 1996 Jul 19; 271(29):17366-71. PubMed ID: 8663343
    [Abstract] [Full Text] [Related]

  • 6. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y, Kyprianou N.
    Cancer Res; 1999 Mar 15; 59(6):1366-71. PubMed ID: 10096572
    [Abstract] [Full Text] [Related]

  • 7. A 7.1 kbp beta-myosin heavy chain promoter, efficient for green fluorescent protein expression, probably induces lethality when overexpressing a mutated transforming growth factor-beta type II receptor in transgenic mice.
    Allegra S, Bouazza L, Benetollo C, Li JY, Langlois D.
    Transgenic Res; 2005 Feb 15; 14(1):69-80. PubMed ID: 15865050
    [Abstract] [Full Text] [Related]

  • 8. Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer.
    Cohen J, Chen Z, Lu SL, Yang XP, Arun P, Ehsanian R, Brown MS, Lu H, Yan B, Diallo O, Wang XJ, Van Waes C.
    Cancer Res; 2009 Apr 15; 69(8):3415-24. PubMed ID: 19351843
    [Abstract] [Full Text] [Related]

  • 9. A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells.
    Dumont N, Arteaga CL.
    Biochem Biophys Res Commun; 2003 Jan 31; 301(1):108-12. PubMed ID: 12535648
    [Abstract] [Full Text] [Related]

  • 10. Quantification of transforming growth factor beta1 (TGFbeta1) mRNA expression in mouse preimplantation embryos and determination of TGFbeta receptor (type I and type II) expression in mouse embryos and reproductive tract.
    Chow JF, Lee KF, Chan ST, Yeung WS.
    Mol Hum Reprod; 2001 Nov 31; 7(11):1047-56. PubMed ID: 11675471
    [Abstract] [Full Text] [Related]

  • 11. The role of Sp1 in the differential expression of transforming growth factor-beta receptor type II in human breast adenocarcinoma MCF-7 cells.
    Liu Y, Zhong X, Li W, Brattain MG, Banerji SS.
    J Biol Chem; 2000 Apr 21; 275(16):12231-6. PubMed ID: 10766860
    [Abstract] [Full Text] [Related]

  • 12. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis.
    Nakamura H, Siddiqui SS, Shen X, Malik AB, Pulido JS, Kumar NM, Yue BY.
    Mol Vis; 2004 Oct 04; 10():703-11. PubMed ID: 15475878
    [Abstract] [Full Text] [Related]

  • 13. Increased TGFbeta type II receptor expression suppresses the malignant phenotype and induces differentiation of human neuroblastoma cells.
    Turco A, Scarpa S, Coppa A, Baccheschi G, Palumbo C, Leonetti C, Zupi G, Colletta G.
    Exp Cell Res; 2000 Feb 25; 255(1):77-85. PubMed ID: 10666336
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of murine cranial suture patency mediated by a dominant negative transforming growth factor-beta receptor adenovirus.
    Song HM, Fong KD, Nacamuli RP, Warren SM, Fang TD, Mathy JA, Cowan CM, Aalami OO, Longaker MT.
    Plast Reconstr Surg; 2004 May 25; 113(6):1685-97. PubMed ID: 15114130
    [Abstract] [Full Text] [Related]

  • 15. Ligand-dependent and -independent interactions with the transforming growth factor type II and I receptor subunits reside in the aminoterminal portion of the ectodomain of the type III subunit.
    Taniguchi A, Matsuzaki K, Nakano K, Kan M, McKeehan WL.
    In Vitro Cell Dev Biol Anim; 1998 Mar 25; 34(3):232-8. PubMed ID: 9557941
    [Abstract] [Full Text] [Related]

  • 16. Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells.
    Koli KM, Arteaga CL.
    Cancer Res; 1997 Mar 01; 57(5):970-7. PubMed ID: 9041203
    [Abstract] [Full Text] [Related]

  • 17. Regulation by adrenocorticotropin (ACTH), angiotensin II, transforming growth factor-beta, and insulin-like growth factor I of bovine adrenal cell steroidogenic capacity and expression of ACTH receptor, steroidogenic acute regulatory protein, cytochrome P450c17, and 3beta-hydroxysteroid dehydrogenase.
    Le Roy C, Li JY, Stocco DM, Langlois D, Saez JM.
    Endocrinology; 2000 May 01; 141(5):1599-607. PubMed ID: 10803567
    [Abstract] [Full Text] [Related]

  • 18. Cell-specificity of transforming growth factor-beta response is dictated by receptor bioavailability.
    Suszko MI, Woodruff TK.
    J Mol Endocrinol; 2006 Jun 01; 36(3):591-600. PubMed ID: 16720726
    [Abstract] [Full Text] [Related]

  • 19. Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)-dependent TGF-beta signaling.
    Upadhyay G, Yin Y, Yuan H, Li X, Derynck R, Glazer RI.
    Proc Natl Acad Sci U S A; 2011 May 10; 108(19):7820-5. PubMed ID: 21518866
    [Abstract] [Full Text] [Related]

  • 20. CCN2/CTGF increases expression of miR-302 microRNAs, which target the TGFβ type II receptor with implications for nephropathic cell phenotypes.
    Faherty N, Curran SP, O'Donovan H, Martin F, Godson C, Brazil DP, Crean JK.
    J Cell Sci; 2012 Dec 01; 125(Pt 23):5621-9. PubMed ID: 22976296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.